2018 Cannabinoids Clinical Trials Events 
Cannabis Law Report
AUGUST 10, 2021
This acquisition is focused on becoming the first and only company solving the puzzle of chronic pain with MDMA-based medicines utilizing clinical trials for the purposes of novel drug development. Cannvalate was established in early 2018 by co-founders Sud Agarwal, Asaf Katz and Darryl Davies. billion in 2030. About Cannvalate.
FloridaMarijuana.net
AUGUST 15, 2018
Evidence-based Complementary and Alternative Medicine published an article titled “Post-Traumatic Stress Disorder: Evidence-Based Research for the Third Millennium” which describes how profound the symptoms of PTSD can be: “Traumatic events are profoundly stressful. Women tend to experience different traumas than men.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
SEPTEMBER 22, 2021
Oxford Cannabinoid Technologies Holdings plc. . Access to Canopy Growth’s cannabinoid library including 335 derivatives and 14 patent families. Accelerated timelines to clinical trials and expansion of drug development pipeline. Phase 1 clinical trials are scheduled for Q3 2022 with Phase 2 trials expected in Q2 2023.
The Joint Blog
APRIL 17, 2020
Over the past few decades, there has been an increased interest in leveraging cannabis and cannabinoids for medicinal purpose. In 2018, ProCon.org has estimated well over 3.5M Reported adverse effect in many clinical trials included amnesia, impaired balance, disturbed attention, dizziness, lethargy, and somnolence.
The Cannigma
MAY 19, 2021
While many countries around the world have legalized or decriminalized cannabis or have eased up on enforcement in recent years, in Japan in 2018 there was a sharp increase in cannabis-related arrests — and 80% of them were possession charges. of Japanese have reported consuming cannabis, as opposed to more than 40% in the US and Canada.
Otherside Farms
JULY 8, 2020
With over 100 potent cannabinoids that constitute the Cannabis plant, the possibilities of health benefits are ample. The healthcare industry is seeing significant investments in clinical trials to prove the health benefits of cannabis. The presence of cannabinoids can reduce muscle ache and ease inflammation.
Cannabis Law Report
JANUARY 4, 2022
Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, has named Simon Allen as Chief Executive Officer and a member of the company’s Board of Directors, effective February 1 st , 2022. Anebulo Pharmaceuticals, Inc.
Expert insights. Personalized for you.
105 
Let's personalize your content